关于PDL1未选择性III期非小细胞肺癌患者同步及巩固度伐利尤单抗联合胸部放疗的安全性与疗效:简要报告
这项单臂2期试验纳入III期非小细胞肺癌患者(不论肿瘤PDL1表达),接受2周期度伐利尤单抗(1500 mg每4周)同步胸部放疗(60 Gy分30次),随后最多13周期巩固度伐利尤单抗。入组10例后因临床结局不佳提前终止;中位随访12个月,5例疾病进展、8例死亡,6例发生15起治疗相关≥3级事件,包括1例4级急性肾损伤和2例致死性肺部事件。12个月无进展生存率为20%(PDL1≥1%为50% vs PDL1不可用或<1%为0%)。
要点
- PDL1未选择性III期非小细胞肺癌中,胸部放疗同步及巩固度伐利尤单抗与高级别毒性和早期疾病进展相关。
- 入组10例后试验因临床结局不佳提前终止;6例发生15起治疗相关≥3级事件,含2例致死性肺部事件。
- 12个月无进展生存率为20%,PDL1≥1%为50% vs PDL1不可用或<1%为0%。
核心结论
- 在PDL1未选择性III期非小细胞肺癌中,胸部放疗联合同步及巩固度伐利尤单抗与高级别毒性和早期疾病进展相关。
研究设计与样本
- 单臂2期试验,纳入III期非小细胞肺癌患者(不论肿瘤PDL1表达)、ECOG体能状态0-1、肺功能充足且放疗野符合标准器官限制。
- 参与者接受2周期度伐利尤单抗(1500 mg每4周)同步胸部放疗(60 Gy分30次),随后最多13周期巩固度伐利尤单抗。
主要发现
- 入组10例患者后试验因临床结局不佳而终止。
- 中位随访12个月,5例患者疾病进展,8例患者死亡。
- 6例患者发生15起治疗相关≥3级事件,包括巩固期1例4级急性肾损伤和2例致死性肺部事件。
- 1例致死性肺部事件发生在同步治疗阶段的活动性吸烟者中,另1例发生在首周期巩固度伐利尤单抗后。
- 12个月无进展生存率主要终点为20%(PDL1≥1%为50% vs PDL1不可用或<1%为0%)。
局限性
- 试验在入组10例患者后因临床结局不佳而终止。
- 中位随访12个月,随访时间有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Consolidative durvalumab, an anti-programmed death ligand 1 (PDL1) immune checkpoint inhibitor, administered after concurrent chemoradiation improves outcomes of patients with locally advanced non-small cell lung cancer (NSCLC) without substantially increasing toxicities. We studied a chemotherapy-free regimen of thoracic radiation therapy (RT) with concurrent and consolidative durvalumab. METHODS AND MATERIALS: This single-arm phase 2 trial enrolled patients with stage III NSCLC (regardless of tumor PDL1 expression), Eastern Cooperative Oncology Group (ECOG) performance status 0-1, adequate pulmonary function, and RT fields meeting standard organ constraints. Participants received 2 cycles of durvalumab (1500 mg every 4 weeks) concurrently with thoracic RT (60 Gy in 30 fractions), followed by up to 13 cycles of consolidative durvalumab. RESULTS: After 10 patients were enrolled, the trial was closed because of poor clinical outcomes. With a median follow-up of 12 months, 5 patients had disease progression and 8 patients died. Six patients experienced 15 treatment-related, grade ≥3 events, including 1 grade 4 acute kidney injury during consolidation and 2 fatal pulmonary events. One fatal pulmonary event occurred during the concurrent phase in an active smoker; the other occurred after the first cycle of consolidative durvalumab. The primary endpoint of progression-free survival at 12 months was 20% (50% for PDL1≥1% vs 0% for PDL1 unavailable or <1%). Median overall survival was not reached, 10.5 months, and 7 months, for PDL1 ≥1%, <1%, and unavailable, respectively. CONCLUSIONS: In PDL1 unselected stage III NSCLC, thoracic RT plus concurrent and consolidative durvalumab is associated with high-grade toxicity and early disease progression.
引用
- Zhang Y, Iyengar P, Montalvo S, et al. Concerning Safety and Efficacy of Concurrent and Consolidative Durvalumab With Thoracic Radiation Therapy in PDL1-Unselected Stage III Non-Small Cell Lung Cancer: Brief Report. Int J Radiat Oncol Biol Phys. 2024. PMID: 39147210. doi:10.1016/j.ijrobp.2024.07.2333
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。